| Literature DB >> 33919261 |
Claudiu T Supuran1, Clemente Capasso2.
Abstract
Carbon dioxide (CO2), a vital molecule of the carbon cycle, is a critical component in living organisms' metabolism, performing functions that lead to the building of compounds fundamental for the life cycle. In all living organisms, the CO2/bicarbonate (HCO3-) balancing is governed by a superfamily of enzymes, known as carbonic anhydrases (CAs, EC 4.2.1.1). CAs catalyze the pivotal physiological reaction, consisting of the reversible hydration of the CO2 to HCO3- and protons. Opportunistic and pathogenic fungi can sense the environmental CO2 levels, which influence their virulence or environmental subsistence traits. The fungal CO2-sensing is directly stimulated by HCO3- produced in a CA-dependent manner, which directly activates adenylyl cyclase (AC) involved in the fungal spore formation. The interference with CA activity may impair fungal growth and virulence, making this approach interesting for designing antifungal drugs with a novel mechanism of action: the inhibition of CAs linked to the CO2/HCO3-/pH chemosensing and signaling. This review reports that sulfonamides and their bioisosteres as well as inorganic anions can inhibit in vitro the β- and α-CAs from the fungi, suggesting how CAs may be considered as a novel "pathogen protein" target of many opportunistic, pathogenic fungi.Entities:
Keywords: CA inhibitors; antifungals; carbon dioxide; carbonic anhydrases CO2-sensing
Mesh:
Substances:
Year: 2021 PMID: 33919261 PMCID: PMC8122340 DOI: 10.3390/ijms22094324
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Sulfonamide/sulfamate/sulfamide of types 1–24 (pink background) and AAZ-EPA (gray background) investigated as fungal CA inhibitors. Legend: AAZ, acetazolamide; MZA, methazolamide; EZA, ethoxzolamide; DCP, dichlorophenamide; DZA, dorzolamide; BRZ, brinznolamide; BZA, benzolamide; TPM, topiramate; ZNS, zonisamide; SLP, sulpiride; IND, indisulam; VLX, valdecoxib; CLX, celecoxib; SLT, sulthiame; HCT, hydrochlorothiazide; FAM, famotidine; EPA, epacadostat.
Inhibition data of human isoenzymes (CA I and CA II) and fungal CAs (MreCA, MgCA, CAS1, CAS2, CAS3; Figure 1) by a stopped-flow CO2 hydrase assay. The other fungal CAs have been previously reviewed by Elleuche and Poggeler (see references [81,82]).
| Inhibitor | KI (nM) * | ||||||
|---|---|---|---|---|---|---|---|
| hCA I 1 | hCA II 1 | MgCA 2 | MreCA 2 | CAS1 1 | CAS2 1 | CAS3 1 | |
|
| 28,000 | 300 | 980 | 412 | 361 | 386 | 90 |
|
| 25,000 | 240 | 24.5 | 462 | 144 | 3480 | 84 |
|
| 79 | 8 | 15.2 | >10,000 | 225 | 3630 | 83 |
|
| 78,500 | 320 | 674 | 404 | 47.1 | 6900 | 560 |
|
| 25,000 | 170 | 17.4 | >10,000 | 323 | 8720 | 726 |
|
| 21,000 | 160 | 7.9 | >10,000 | 241 | 7650 | 441 |
|
| 8300 | 60 | 11.6 | 459 | 43.2 | 7360 | 585 |
|
| 9800 | 110 | 12.1 | >10,000 | 79.6 | 9120 | 2078 |
|
| 6500 | 40 | 34.9 | >10,000 | 580 | 12,000 | 712 |
|
| 7300 | 54 | 54.3 | >10,000 | >50,000 | 23,500 | 350 |
|
| 5800 | 63 | 9 | 676 | 890 | 18,700 | 235 |
|
| 8400 | 75 | 9.2 | >10,000 | 3350 | >50,000 | 90 |
|
| 8600 | 60 | 7900 | >10,000 | 8650 | 48.1 | 88 |
|
| 9300 | 19 | 8500 | >10,000 | 7215 | 280 | 94 |
|
| 5500 | 80 | 23.6 | >10,000 | 3160 | 143 | 605 |
|
| 9500 | 94 | 10.4 | 651 | 4520 | 92.5 | 82 |
|
| 21,000 | 125 | 6.3 | >10,000 | >50,000 | 390 | 507 |
|
| 164 | 46 | 6.8 | >10,000 | 4443 | 3250 | 226 |
|
| 109 | 33 | 3500 | 779 | 475 | 6760 | 91 |
|
| 6 | 2 | 23.4 | 91 | 363 | 9880 | 85 |
|
| 69 | 11 | 11.8 | 740 | 4550 | 4060 | 95 |
|
| 164 | 46 | 9.4 | 374 | 1985 | 25,200 | 85 |
|
| 109 | 33 | 4530 | >10,000 | 282 | >50,000 | 89 |
|
| 95 | 30 | 256 | >10,000 | 294 | >50,000 | 84 |
|
| 250 | 12 | 7600 | 10 | 445 | 816 | 94 |
|
| 50 | 14 | 7455 | 390 | 421 | 8140 | 91 |
|
| 25 | 8 | 3800 | 379 | 440 | 3170 | 95 |
|
| 1200 | 38 | 34.6 | 306 | 1220 | 5790 | 73 |
|
| 50,000 | 9 | 7900 | 81 | 360 | 742 | 274 |
|
| 45,000 | 3 | 8400 | 70 | 451 | 739 | 61 |
|
| 15 | 9 | 48.2 | 715 | 2115 | 410 | 54 |
|
| 250 | 10 | 146 | 383 | 414 | 673 | 363 |
|
| 56 | 35 | 765 | >10,000 | 1820 | 1885 | 710 |
|
| 1200 | 40 | 32 | 485 | 1715 | 670 | 493 |
|
| 31 | 15 | n.d. | 87 | 4240 | 216 | 94 |
|
| 54,000 | 43 | 3150 | 77 | 4425 | 3730 | 831 |
|
| 50,000 | 21 | 3480 | 140 | 2513 | 857 | 669 |
|
| 374 | 9 | n.d. | 67 | 3210 | 496 | 4838 |
|
| 18,540 | 5959 | n.d. | 620 | 5280 | 7075 | 191 |
|
| 328 | 290 | n.d. | 850 | 3350 | 6680 | 545 |
|
| n.d. | n.d. | n.d. | >10,000 | n.d. | n.d. | n.d. |
|
| n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
* Errors were in the range of ±5–10% on three different assays. 1 From reference [83] and [84]; 2 From reference [85]; n.d.: not detected.
Inhibition constants obtained using anionic inhibitors versus the α-CA isozymes of human origin (hCA I and hCA II), and Table 1. CAS2, CAS3; for the acronyms, see the text) by a stopped flow CO2 hydrase assay.
| Anion | KI (mM) * | ||||||
|---|---|---|---|---|---|---|---|
| hCA I 1 | hCA II 1 | MgCA 2 | MreCA 2 | CAS1 1 | CAS2 1 | CAS3 1 | |
| F− | >300 | >300 | 7.13 | >50 | >100 | >100 | >100 |
| Cl− | 6 | 200 | 7.98 | >50 | 9.2 | >100 | >100 |
| Br− | 4 | 63 | 18.6 | >50 | 9.3 | >100 | >100 |
| I− | 0.3 | 26 | 8.73 | 8.6 | 8.6 | 7.7 | 9.9 |
| CNO− | 0.0007 | 0.03 | 6.81 | >50 | 0.9 | 0.82 | 3.2 |
| SCN− | 0.2 | 1.60 | 8.39 | >50 | 5.4 | 5.6 | 7.3 |
| CN− | 0.0005 | 0.02 | 7.19 | >50 | 0.94 | 0.75 | 8.7 |
| N3− | 0.0012 | 1.51 | 45.2 | >50 | >100 | 6.1 | 7.2 |
| NO2− | 8.4 | 63 | 7.56 | >50 | >100 | >100 | 8.3 |
| NO3− | 7 | 35 | 8.13 | 9 | >100 | >100 | 8.5 |
| HCO3− | 12 | 85 | 0.59 | 0.86 | 3.3 | 7.3 | >100 |
| CO32− | 15 | 73 | >100 | >50 | >100 | 8.8 | 8 |
| HSO3− | 18 | 89 | >100 | >50 | 3.3 | 7.3 | >100 |
| SO42− | 63 | >200 | 19.5 | >50 | >100 | 4.8 | >100 |
| HS− | 0.0006 | 0.04 | 11.9 | >50 | 0.89 | 8.5 | 8.3 |
| SnO32− | 0.57 | 0.83 | 5.07 | 0.56 | 4.3 | 0.92 | 7.9 |
| SeO42− | 118 | 112 | 7.41 | 1.7 | 2.4 | 9.2 | 3.4 |
| TeO42− | 0.66 | 0.92 | 5.75 | 0.56 | 2.5 | 6.3 | 8.1 |
| OsO52− | 0.92 | 0.95 | 6.16 | 8.5 | n.d. | n.d. | n.d. |
| P2O74− | 25.77 | 48.50 | 6.03 | >50 | 3.1 | 0.96 | >100 |
| V2O74− | 0.54 | 0.57 | 6.89 | >50 | >100 | 1.4 | >100 |
| B4O72− | 0.64 | 0.95 | 8.45 | 0.4 | 6.7 | 6.9 | 5.9 |
| ReO4− | 0.11 | 0.75 | 16.7 | >50 | 8.2 | >100 | 8.8 |
| RuO4− | 0.101 | 0.69 | 8.82 | 7.4 | 3.9 | >100 | 9.2 |
| S2O82− | 0.107 | 0.084 | >100 | >50 | 5 | >100 | >100 |
| SeCN− | 0.085 | 0.086 | 1.73 | 0.65 | 2.9 | 9.3 | 7.1 |
| CS32− | 0.0087 | 0.0088 | 1.77 | 0.92 | 0.79 | >100 | 8.6 |
| Et2NCS2− | 0.00079 | 0.0031 | 0.30 | 0.075 | 0.38 | 0.93 | 0.89 |
| CF3SO3− | n.d. | n.d. | 2.28 | 4.5 | n.d. | n.d. | n.d. |
| PF6− | n.d. | n.d. | 6.47 | 3.9 | n.d. | n.d. | n.d. |
| ClO4− | >200 | >200 | >100 | 9.2 | >100 | >100 | >100 |
| BF4− | >200 | >200 | >100 | 383 | >100 | >100 | >100 |
| FSO3− | 0.79 | 0.46 | 4.06 | >50 | 0.93 | 8.4 | >100 |
| NH(SO3)22− | 0.31 | 0.76 | 21.4 | >50 | 0.88 | 9.2 | >100 |
| H2NSO2NH | 0.31 | 1.13 | 0.094 | 0.72 | 0.084 | 0.048 | 0.094 |
| H2NSO3H | 0.021 | 0.39 | 0.083 | 7.7 | 0.069 | 0.072 | 0.095 |
| Ph-B(OH)2 | 58.6 | 23.1 | 0.089 | 8.7 | 0.009 | 0.056 | 0.097 |
| Ph-AsO3H2 | 31.7 | 49.2 | 0.090 | 0.83 | 0.035 | 0.054 | 0.091 |
* Errors were in the range of ±5–10% on three different assays. 1 From reference [87]; 2 From reference [88]; n.d.: not detected.
Figure 2Active site view of Can2 (pdb 2W3N) complexed to the anion inhibitor acetate [45]. Protomers A and B are colored green and cyan respectively. Residues from protomers A and B are labeled black and light blu, respectively. The Zn2+ ion, represented as a grey sphere, is coordinated by two cysteines and one histidine residue from monomer A and by one acetate ion as a ligand. The salt bridge in the Asp-Arg dyad is represented as a yellow dashed line.